Vectura Group (VEGPF) Stock Price, News & Analysis

Company Overview

Vectura Group plc is a UK-based specialist in the development and manufacturing of inhaled therapies for respiratory diseases. The company offers end-to-end services spanning formulation design, device engineering, analytical testing, clinical supply and regulatory support. Its expertise covers a broad range of inhalation platforms, including dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), soft-mist inhalers and nebulizer systems. Vectura works both on its own proprietary assets and as a contract development and manufacturing organization (CDMO) for pharmaceutical and biotech partners.

Founded in 1997 as a spin-out from Imperial College London, Vectura built its business around innovation in pulmonary drug delivery. The company completed an initial public offering on the London Stock Exchange in 2004 and grew through collaborations and licensing agreements with major pharmaceutical firms. Over its history, Vectura has advanced multiple clinical-stage programs targeting conditions such as asthma, chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.

Headquartered in Cambridge, England, Vectura maintains R&D and manufacturing sites in the UK and a presence in the United States and continental Europe to serve global markets. In May 2021, Vectura became a wholly owned subsidiary of Philip Morris International, enabling deeper investment in inhaled therapy innovation within a larger healthcare research network. The company continues to focus on delivering inhalation solutions that improve patient outcomes and streamline development pathways for its partners.

Key Stats

• Today's Range: $1.77 to $1.77
• 50-Day Range: $1.77 to $1.77
• 52-Week Range: $1.64 to $2.74
• Volume: N/A
• Average Volume: 2,185 shs
• Market Capitalization: $1.07 billion
• P/E Ratio: 6.81
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:VEGPF
• CIK: N/A
• Web: www.vectura.com
• Phone: 441249667700
• Fax: N/A
• Employees: 502
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 6.81
• Forward P/E Ratio: 19.67
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $244.76 million
• Price / Sales: 4.37
• Cash Flow: $0.28 per share
• Price / Cash Flow: 6.33
• Book Value: $1.16 per share
• Price / Book: 1.53

Miscellaneous

• Outstanding Shares: 604,260,000
• Free Float: N/A
• Market Cap: $1.07 billion
• Optionable: Not Optionable
• Beta: 0.37